Ann: Expanded Heart Protection Discovery for Zantrene, page-158

The patent system was set up to incentivise big pharma in taking the gamble. amgen has already enjoyed big profits from its 15 or whatever years of patent protection for Carfilzomib. Do they really deserve to double-dip and win another 15 years of patent protection by doing a risk-less, cheap combo tweak with Zantrene?

Would allowing such a thing be in the true spirit of patent protection for companies taking on huge, expensive gambles?

I am not saying Zantrene shouldn’t go ahead and hop into bed with Amgen regarding this possible combo deal. after all, it is legal and therefore sensible. I am saying a smarter regulatory system would forbid it, because it, in my opinion, stinks!